Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

NCT03277482 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
16
Enrollment
OTHER
Sponsor class

Stopped Expansion cohort was not open

Conditions

Interventions

Sponsor

Dana-Farber Cancer Institute

Collaborators